As TRIB3 was reported to connect with NSCLC progression or response to therapeutic agents with some controversial opinions41–45, we evaluated the genetic depletion of TRIB3 on NSCLC progression. This evidence concerns the gene TRIB3 and non-small cell lung carcinoma.